156 related articles for article (PubMed ID: 32571824)
1. How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide.
Köser CU; Cirillo DM; Miotto P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571824
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China.
Liu W; Chen J; Shen Y; Jin J; Wu J; Sun F; Wu Y; Xie L; Zhang Y; Zhang W
Clin Microbiol Infect; 2018 Sep; 24(9):1016.e1-1016.e5. PubMed ID: 29288021
[TBL] [Abstract][Full Text] [Related]
3. Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of
Tam KK; Leung KS; Siu GK; Chang KC; Wong SS; Ho PL; Leung EK; Yam WC
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31189582
[TBL] [Abstract][Full Text] [Related]
4. Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.
Whitfield MG; Engelthaler DM; Allender C; Folkerts M; Heupink TH; Limberis J; Warren RM; Van Rie A; Metcalfe JZ
J Clin Microbiol; 2022 Jan; 60(1):e0190721. PubMed ID: 34757831
[TBL] [Abstract][Full Text] [Related]
5. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y
Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115
[TBL] [Abstract][Full Text] [Related]
6. Non-
Werngren J; Alm E; Mansjö M
J Clin Microbiol; 2017 Jun; 55(6):1920-1927. PubMed ID: 28404681
[TBL] [Abstract][Full Text] [Related]
7. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.
Davies AP; Billington OJ; McHugh TD; Mitchison DA; Gillespie SH
J Clin Microbiol; 2000 Oct; 38(10):3686-8. PubMed ID: 11015384
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
Che Y; Bo D; Lin X; Chen T; He T; Lin Y
BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.
Mok S; Roycroft E; Flanagan PR; Montgomery L; Borroni E; Rogers TR; Fitzgibbon MM
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0261720. PubMed ID: 33972244
[TBL] [Abstract][Full Text] [Related]
10. Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Aono A; Chikamatsu K; Yamada H; Kato T; Mitarai S
Antimicrob Agents Chemother; 2014 Aug; 58(8):4928-30. PubMed ID: 24867972
[TBL] [Abstract][Full Text] [Related]
11. pncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects.
Wu X; Lu W; Shao Y; Song H; Li G; Li Y; Zhu L; Chen C
Infect Genet Evol; 2019 Aug; 72():147-150. PubMed ID: 30447296
[TBL] [Abstract][Full Text] [Related]
12. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
Jonmalung J; Prammananan T; Leechawengwongs M; Chaiprasert A
BMC Microbiol; 2010 Aug; 10():223. PubMed ID: 20727143
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide Susceptibility and
Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Masood N; Nadeem T; Khan AS; Afzal MT
BMC Infect Dis; 2019 Feb; 19(1):116. PubMed ID: 30728001
[TBL] [Abstract][Full Text] [Related]
16. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.
Werngren J; Sturegård E; Juréen P; Ängeby K; Hoffner S; Schön T
Antimicrob Agents Chemother; 2012 Mar; 56(3):1253-7. PubMed ID: 22203587
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.
Juréen P; Werngren J; Toro JC; Hoffner S
Antimicrob Agents Chemother; 2008 May; 52(5):1852-4. PubMed ID: 18316515
[TBL] [Abstract][Full Text] [Related]
18. Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan.
Huang HT; Lin WH; Chan TH; Jou R
J Microbiol Immunol Infect; 2023 Dec; 56(6):1236-1244. PubMed ID: 37690869
[TBL] [Abstract][Full Text] [Related]
19. Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm.
Simons SO; van der Laan T; Mulder A; van Ingen J; Rigouts L; Dekhuijzen PN; Boeree MJ; van Soolingen D
Clin Microbiol Infect; 2014 Oct; 20(10):1015-20. PubMed ID: 24890253
[TBL] [Abstract][Full Text] [Related]
20. [Detection of pncA mutation associated with pyrazinamide resistance in Mycobacterium tuberculosis by high-resolution melting cure analysis].
Hong CY; Wang F; Liu XL
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):198-201. PubMed ID: 23856143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
